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Abstract
The minimally invasive midvastus (MMV) surgical approach for total knee arthroplasty (TKA)
is a less invasive technique that has been proposed to accelerate recovery over standard TKA,
however, advantages are not yet definitively established. We investigated the cost-effectiveness
of MMV TKA versus the standard medial parapatellar (MPP) approach for TKA alongside a
randomized controlled trial in patients with knee osteoarthritis. Patients reported resource use as
well as indirect costs, and health outcomes were measured using the EQ-5D-5L and the Western
Ontario and McMaster Universities Osteoarthritis Index over the 12-month study period. The
results of our net benefit regression analysis suggest MMV TKA may be cost-effective compared
to MPP TKA from the payer perspective at willingness-to-pay (WTP) values between $1000 and
$2000, and WTP values between $2000 and $20,000 from the societal perspective.
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Summary for Lay Audience
For patients with advanced knee osteoarthritis (OA), total knee replacement (TKR) is an
established surgical procedure that has been shown to improve pain, function, and quality of life.
Over the years, less invasive surgical approaches have been developed in efforts to improve
short-term recovery, reduce complications, and shorten the length of stay in hospital following
TKR. The midvastus approach is one such technique. The potential advantage of the midvastus
approach over traditional approaches is that less soft tissue in the leg is cut during surgery, which
may allow for faster recovery and thus reduce the length of stay in hospital.

A shorter length of stay may reduce the hospital costs of TKR, although it is unknown whether
the potential financial savings will be outweighed by possible complications related to early
discharge from the hospital.

Therefore, the aim of this study was to evaluate the clinical outcomes and costs of TKR using a
midvastus surgical approach compared to the standard medial parapatellar approach in patients
with knee OA. We randomly assigned consenting patients scheduled to have TKR to either
surgical approach and followed them for 12-months.

Patients completed questionnaires on their health care resource use (e.g., number of physician
visits, tests, medications) and indirect costs (e.g, time off work/volunteering) related to their
surgery. They also completed surveys on health outcome measures such as health-related quality
of life, pain, and movement before surgery, two-weeks, six-weeks, three-months, and 12-months
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after surgery. We calculated the average total costs and health benefits incurred by patients in
each group over the 12-month study period.

We found patients who had TKR with the midvastus approach experienced slightly greater
health benefits than patients who had standard medial parapatellar TKR. Midvastus TKR patients
also incurred fewer costs when considering societal costs which includes direct and indirect
costs. Our findings highlight the importance of investigating patient-reported outcome measures
and indirect costs. These results will help inform a future study evaluating the safety and costeffectiveness of outpatient TKR, where patients are discharged from the hospital on the same day
as their surgery.
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Chapter 1
1.1 Introduction
Osteoarthritis (OA) is a degenerative joint disease often causing localized pain and reduced
mobility (Woolf & Pfleger, 2003). This condition can significantly impact the physical and
psychosocial well-being of patients (Sharma & Felson, 1998), and presents a substantial financial
burden to healthcare systems and society as a whole (Gupta et al., 2005; Marshall et al., 2015).
Nearly 1 in 3 people over the age of 65 are affected by OA, and the prevalence is expected to rise
as risk factors for developing OA become more common (Arthritis Alliance of Canada [AAC],
2011; Hawker, 2019). Therefore, it is important to investigate the cost-effectiveness of
treatments for OA to optimize health gains given the constraints on health care resources.

For patients with advanced knee osteoarthritis, total knee arthroplasty (TKA) is an established
surgical procedure that has been shown to improve pain, function, and health-related quality of
life (Pollock et al., 2016; Bourne et al., 2010). Over the years, less invasive surgical techniques,
including the midvastus approach, have been developed in efforts to improve short-term
recovery, reduce complications, and shorten the length of stay following TKA. The potential
advantage of the midvastus approach is that a large portion of the insertion of the vastus medialis
on the quadriceps tendon is preserved during surgery which may allow for accelerated recovery
and thus a reduced length of stay in hospital following surgery (Haas et al., 2004; Berger et al,
2005; Laskin, 2005).
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A shorter hospital stay is one means of reducing the overall costs of TKA. Although improved
efficiency is important in healthcare delivery, we must also consider the safety, effectiveness,
and patient satisfaction associated with new models of care. Further, it is unknown whether the
potential financial savings of minimally invasive TKA will be outweighed by possible additional
postoperative costs, such as increased readmissions and decreased quality of care.

Therefore, the objective of this study was to evaluate the cost-effectiveness of TKA using a
minimally invasive midvastus (MMV) surgical approach compared to the standard medial
parapatellar (MPP) approach in patients with knee OA based on a 12-month randomized
controlled trial (RCT). Our findings will be used to inform the protocol of a future RCT
investigating the safety and cost-effectiveness of outpatient total knee arthroplasty.
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1.2 Literature Review
1.2.1 Osteoarthritis
Osteoarthritis is the most common type of arthritis (Murray et al., 1996), affecting nearly 1 in 3
people over the age of 65 (AAC, 2011). This degenerative musculoskeletal disease affects all
structures within a joint (Felson et al., 2006) and is characterized by loss of joint cartilage that
leads to localized pain, reduced joint range of motion and mobility, and lower quality of life
(Hunter et al., 2008). In Canada, OA is one of the leading causes of disability, as well as a major
economic burden (Marshall et al., 2015). The number of people living with OA is projected to
double by 2040 as populations age and life expectancy extends (AAC, 2011). The increasing
prevalence of OA risk factors, including obesity, physical inactivity, and joint injury, are also
likely contributing to the rising rates of OA (Hawker, 2019; Puig-Junoy & Ruiz Zamora, 2015).

1.2.1.1 Disease burden in Canada
Studies on the prevalence of osteoarthritis have shown that approximately 3.9 million Canadians
are living with symptomatic OA (PHAC, 2020). Osteoarthritis is not only responsible for a very
high number of primary health care visits and overall hospital costs, but there is also a significant
socio-economic burden (Li et al., 2006). A survey by Gupta et al. (2005) estimated Canadian
patients over the age of 55 with hip or knee arthritis incurred $2300 in direct costs and $12,900
in indirect costs annually. These non-healthcare-related indirect costs took form in time lost from
employment for patients and for unpaid informal caregivers, with caregiver time accounting for
40% of indirect costs. Another study by Xie et al. (2007) estimated the annual direct costs per
patient to be US$2878 and the indirect costs to be US$9847 in Canada. As the Canadian
population ages, osteoarthritis will become an increasing burden for individuals and the health
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care system (Birtwhistle et al., 2015). The direct costs of OA in Canada were projected to
increase from $2.9 billion to $7.6 billion from 2010 to 2030, with hospitalizations for joint
replacement accounting for the highest costs (Sharif et al., 2015).

1.2.1.2 Osteoarthritis of the Knee
Almost any synovial joint can be affected by osteoarthritis, although weight-bearing joints such
as the knees and hips are the most commonly impacted (PHAC, 2010). Knee OA specifically
impacts over 10% of the older adult population (AAC, 2011; Zhang & Jordan, 2010) and
accounts for 83% of OA disability (Vos et al., 2012).

The lifetime risk of developing symptomatic OA in at least one knee is estimated to be 39.8% for
men and 46.8% for women, with significantly higher odds seen in those who possessed risk
factors including obesity and history of knee injury (Murphy et al., 2008). Other common risk
factors for OA include age, sex, genetic predisposition, and mechanical factors, including
malalignment and abnormal joint shape.

The course of the disease can vary but is often progressive. Over time the hyaline articular
cartilage, which covers and protects the ends of bones, breaks down, and bony remodeling
occurs. This breakdown was once thought to be caused by the wear and tear associated with
aging, however, osteoarthritis is now understood to be the result of disruption of the natural
cartilage remodeling process (PHAC, 2010; Kraus et al., 2015). As articular cartilage is lost, the
subchondral bone becomes exposed, leading to joint space narrowing and bone-on-bone
articulation. The continuous friction between the bones can cause excessive bone remodeling
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(formation of osteophytes and subchondral bone sclerosis) and thickening of the capsule (Lories
& Luyten, 2011; Loeser et al., 2012). Inflammation of the synovium as well as overproduction of
matrix-degrading enzymes, leading to destabilization of the joint, and abnormal joint loading are
also often seen with knee osteoarthritis (Blagojevic et al., 2010; Felson et al., 2000; Felson,
2009; Troeberg & Nagase, 2012).

Knee OA is commonly clinically characterized by joint pain that is gradual in onset and worse
with activity, tenderness, limitation of movement, crepitus, and variable degrees of local
inflammation (Hunter et al. 2008; Kraus et al., 2015).

Progression of OA cannot be reversed, and no disease-modifying agents for the treatment of
knee osteoarthritis currently exist, although interventions have been developed to reduce
symptoms of knee OA and improve function (Woolf & Pfleger, 2003). Therapeutic exercise,
weight management, and pain medications may help relieve symptoms (Dunlop et al., 2011;
Bijlsma & Knahr, 2007; PHAC, 2010). In cases of severe osteoarthritis, when conservative
management fails, surgical treatment, including knee arthroplasty, may be considered (Lützner et
al., 2009).

1.2.2 Total Knee Arthroplasty
Total knee arthroplasty (TKA), also known as total knee replacement, is a surgical procedure to
replace the arthritic parts of the bones at the knee joint (the tibia, femur, and sometimes the
patella) with an orthopedic prosthesis. TKA is considered for patients with severe knee
osteoarthritis, rheumatoid arthritis, avascular necrosis, bone tumors, and knee fracture, although
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osteoarthritis was the primary diagnosis for 99.4% of primary total knee arthroplasty patients in
Canada from 2019-2020 (CIHI, 2021). The surgery has been shown to be highly effective,
resulting in significant improvements in pain, functioning, and health-related quality of life
(Brandes et al., 2011; Shan et al., 2015), but is also very costly. The average inpatient cost is
more than $9,000 per procedure and accounts for more than 594,000 acute care bed days in
Canada annually (CIHI, 2018). Total knee replacements are among the top 3 inpatient surgeries
performed in Canada, and in the last five years, the number of TKAs performed has increased by
17.1% (CIHI, 2021). Given the frequency at which the procedure is performed, it is the focus of
continuous analysis and improvement (King et al., 2011; Lan et al., 2020).

1.2.2.1 The Medial Parapatellar and Midvastus Surgical Approaches
Two commonly used surgical approaches that have been shown to be safe for TKA are the
medial parapatellar and the midvastus approach.

The medial parapatellar approach is the most commonly used approach for total knee
arthroplasty and is usually completed using an anterior incision approximately 18 cm long. With
this approach, the quadriceps tendon is split in line with the fibers, leaving a cuff of tendon
attached to the vastus medialis muscle, and the patella is everted (Laskin et al., 2004). This
approach allows for excellent exposure of the joint and surgical visualization (Weinhardt et al.,
2004, Migliorini et al., 2020), however, the damage on the insertion of the vastus medialis on the
quadriceps tendon can result in a weakened extensor mechanism and unsatisfactory functional
outcomes (Boerger et al., 2005; Haas et al., 2004). Additionally, with this approach, the patellar
blood supply is disrupted, which may increase surgical complications such as button loosening,
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patellar dislocation, and anterior knee pain (Brick & Scott, 1988; Berger et al., 1998; Roysam &
Oakley, 2001). Overall, the standard medial parapatellar approach for TKA has had excellent
surgical results but can result in demanding and lengthy recovery periods, which may contribute
to patient dissatisfaction (Laskin et al., 2004; King at al., 2007; Anderson et al., 1996; Maloney,
2002).

Aiming to reduce recovery time and achieve better postoperative results, less invasive
approaches for TKA were developed (Tria & Scuderi, 2015). The midvastus approach is one
surgical technique that was developed to reduce the injury to the quadriceps tendon and
minimize the disruption to patellar blood supply (Haas et al., 2004). With this approach, the
vastus medialis muscle is divided in the direction of its fibers, as opposed to the traditional
method of splitting the quadriceps tendon above the patella (Engh & Parks, 1998). It was
suggested that this might allow for patients to experience less pain, and early restoration of range
of motion (ROM) and extensor mechanism strength, compared to the medial parapatellar
approach (Haas at al., 2006; Bonutti et al., 2004). This accelerated recovery was also proposed to
allow for a shorter hospital stay, although these theoretical advantages are still being evaluated in
clinical practice (Tria & Coon, 2003; Haas et al., 2004; Berger et al., 2005; Laskin, 2005).
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Figure 1.1: The standard medial parapatellar and midvastus approaches for total knee
arthroplasty.

The definition of minimally invasive surgery (MIS) TKA is not yet standardized. Some authors
have suggested MIS TKA generally involves a skin incision of less than 14 cm and incisions
between 2-3 cm into the quadriceps muscle (Laskin et al., 2004; Tenholder et al., 2005; Tria &
Scuderi, 2015). Others suggest MIS TKA includes a smaller incision, typically does not require
eversion of the patella, and involves less quadriceps splitting (Leopold, 2009). The midvastus
and medial parapatellar approaches can both be performed using either standard or minimally
invasive techniques (Ongoo et al., 2020). However, the medial parapatellar approach is still the
most commonly used standard approach for TKA, while the midvastus approach is often
performed using minimally invasive techniques. In a meta-analysis comparing the midvastus and
medial parapatellar approaches by Liu et al. (2014), 18 of the 22 included RCTs used minimally
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invasive techniques in the midvastus group, compared to standard medial parapatellar TKA. Xu
et al. (2014) also conducted a meta-analysis including only studies that compared minimally
invasive midvastus TKA with standard medial parapatellar TKA. In an earlier meta-analysis
comparing midvastus TKA to standard medial parapatellar TKA by Alcelik et al. (2012), nine
studies where minimally invasive techniques were used for midvastus TKA and nine studies
where standard techniques was used for midvastus TKA were included. They found similar
trends for all outcomes measured in a subgroup analysis comparing the minimally invasive
approach to the standard approach for midvastus TKA.

Overall, these meta-analyses found the results from the studies analyzing the differences between
midvastus and medial parapatellar TKA are conflicting. All authors have reported differences in
short-term outcomes but a reduction in significant clinical advantages over time (Alcelik et al.,
2012; Liu et al., 2014; Xu et al., 2014). The midvastus approach was associated with
significantly improved knee range of motion and decreased anterior knee pain visual analog
scale (VAS) scores at one to two weeks postoperative, however, there were no statistical
differences in knee society score (KSS), VAS, or ROM beyond six weeks (Xu et al., 2014; Liu et
al., 2014). Additionally, the midvastus approach has been associated with significantly longer
operative time when compared to the standard medial parapatellar approach. This is possibly due
to the greater surgical steps and reduced operation field required for less invasive techniques (Liu
et al., 2014). Some investigators have raised questions about the risk of component malalignment
and the learning curve associated with performing new minimally invasive techniques (Dalury
and Dennis, 2005; King et al., 2007).
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In terms of the time to perform straight leg raise, lateral retinacular release, blood loss, hospital
stay, and postoperative complications (wound infection, deep vein thrombosis), no differences
have been found between patients undergoing midvastus TKA compared to medial parapatellar
TKA (Liu et al., 2014).

Other less invasive TKA approaches include the quadriceps-sparing approach, and the subvastus
approach (Tenholder et al., 2005). Each approach has its advantages, however, due to the
difficulty of the operations, limited visualization, and longer learning curve, these approaches
have not gained as much popularity (Haas et al., 2004; Liu et al., 2014; Lin et al., 2020).

1.2.3 Outpatient Total Knee Arthroplasty
Overall improvements in surgical and anesthetic techniques, as well as accelerated clinical care
pathways, have led to a reduction in the rate of complications and shorter lengths of stay
following TKA. These clinical pathways involve the application of multidisciplinary strategies
by various healthcare professionals, including extensive preoperative patient education, early
mobilization, meticulous monitoring, and early preventive intervention for common
postoperative medical complications (Pollock et al., 2016; Berger et al., 2009). Some authors
have reported that reducing the length of stay in the hospital following joint arthroplasty can
reduce costs without compromising patient outcomes (Bozic & Beringer, 2007; Teeny et al.,
2005; Berger et al., 2009; Isaac et al., 2005). Today the average length of stay in the hospital
following surgery is 3 days, although TKA is increasingly being performed as an outpatient
surgery – where the patient is discharged from the hospital on the same day as their surgery
(CIHI, 2021). Over the last five years, there has been over a 500% increase in the number of
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outpatient knee replacements performed in Canada, however outpatient procedures still only
represent 1.3% of all total knee arthroplasties performed (CIHI, 2021). Initially, there was
concern that patients who underwent outpatient total joint arthroplasty (TJA) may experience
complications related to early discharge and require additional services post-discharge, however,
studies have found that outpatient THA and TKA can be safe and effective when performed in
appropriately selected patients (Berger et al, 2009; Berger et al., 2005; Kolisek et al., 2009;
Pollock et al., 2016; Cassard et al., 2018; Mariorenzi et al., 2020). A systematic review of the
literature by Pollock et al. (2016) found no increase in readmission rates or perioperative
complications, and a high level of satisfaction among patients who underwent outpatient
procedures.

No surgical approach is regarded as the standard for outpatient TKA, although most associate
surgical approaches that minimize soft tissue damage with the ability to safely discharge patients
home quicker (Berger et al., 2005; Berger et al., 2006). In an early study by Berger et al. (2005),
a minimally invasive quadriceps-sparing approach was used to enable patients to go home the
same day as their surgery. In a study by Kolisek et al. (2009), patients in both the inpatient and
outpatient group received a TKA with medial parapatellar approach using a 10- to 13-cm
incision, avoiding patella eversion. In this study, however, outpatients were defined as patients
who were discharged within 23 hours of surgery rather than on the same day as surgery.

1.2.4 Health Economics
As healthcare costs rise and societal resources become more scarce, efficient allocation of
healthcare dollars is crucial (Drummond et al., 2005). The constraints of the current fiscal
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climate require that decision-makers choose treatments that provide the best quality of care and
optimize health benefits while minimizing costs. To better support these decisions, evidencebased research providing information on economic efficiency and value for money is necessary
(Health Council of Canada, 2009).

Economic evaluation provides a method of comparing alternative courses of action in terms of
costs and clinical consequences to help prioritize different healthcare strategies. These analyses
help support investment in interventions that generate the greatest health value compared to a set
of alternatives. With the growing burden of osteoarthritis as well as the high costs associated
with total knee arthroplasty, it is important to investigate cost-effective strategies that optimize
health gains given limited healthcare resources.

1.2.4.1 Cost-effectiveness of Midvastus Total Knee Arthroplasty
Several studies have evaluated the clinical effectiveness of midvastus TKA (Alcelik et al., 2012;
Liu et al., 2014; Xu et al., 2014; Aslam et al., 2017; Lin et al., 2020), however, we found no
studies that have investigated the economic implications of this approach.

A few authors have studied the costs associated with other minimally invasive approaches for
TKA, although none have prospectively investigated costs after hospital discharge.
Coon et al. (2005) retrospectively reviewed the procedural charges of patients who received a
minimally invasive TKA (with the MIS Mini-Incision™ or MIS Quadriceps-Sparing™
techniques), compared to standard TKA. They found the cost of MIS TKA to be on average
US$8600 (26%) less compared to traditional TKA. They mention this cost-saving was seen
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despite requiring a more expensive implant for MIS TKA and prolonged tourniquet times use
due to an early learning curve, although they do not specify the source of the cost reduction.
Additionally, this study only presented patient charges and not actual hospital costs and did not
take post-discharge medication, rehabilitation, or time off work costs into consideration.

A study by King et al. (2011) also found MIS TKA to be associated with lower patient charges,
although the magnitude of the difference was much smaller. They conducted a retrospective
analysis on the inpatient charges of patients undergoing TKA with a minimally invasive
quadriceps-sparing approach compared to the standard medial parapatellar approach and found
MIS TKA patients to have slightly higher operating room costs but lower acute care costs
resulting in a difference of US$1047 (7.2%) in the total inpatient charges.

These studies provide some evidence that minimally invasive TKA may be cost-saving in the
peri-operative period from the payer perspective, however, there were some limitations to these
studies that warrant further investigation.

These studies only considered the direct costs of the procedure or inpatient hospital charges;
however, it is important to consider costs beyond hospital discharge. Potential financial savings
in the hospital may be outweighed by additional postoperative costs, such as increased
emergency room or physician visits, or decreased quality of care due to early discharge from the
hospital. Given the proposed advantages of less invasive surgery such as earlier return to
function, the costs associated with outpatient physical therapy and other rehabilitation costs, as
well as indirect costs, should also be considered. Indirect costs include loss of wages or
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productivity losses, as well as time off for caregivers. Previous studies on the indirect costs
associated with musculoskeletal disorders have estimated these costs may be three to five times
greater than direct medical costs incurred by patients (Gupta et al., 2005; Leardini et al., 2004).
The burden on caregivers is high in the early post-operative period following TKA (Zadzilka et
al., 2018). Caregivers often assist with performing household chores, transportation, taking
medication, and personal care for the first 7 to 30 days following surgery (Manohar et al., 2014;
Zadzilka et al., 2018). With enhanced recovery care pathways and early discharge, more
assistance may be required from caregivers as postoperative rehabilitation and care activities
shift from the inpatient setting to the home. Thus, the potential impact on caregivers should also
be considered as more responsibility is placed on them earlier (van den Berg et al., 2004; Zomar,
2020).

Additionally, as some studies have found minimally invasive TKA to be associated with
component malalignment and an increase in the need for revision surgery (Dalury & Dennis,
2005; Barrack et al., 2009), analyzing direct medical costs over a longer time may influence
results.

Another limitation of these studies was that they were non-randomized and included early
learning curve patients with prolonged tourniquet times. Increased operation times have been
associated with minimally invasive techniques; however, studies have shown operating times
reduce as surgeons gain familiarity with the technique (King et al., 2007; Migliorini et al., 2020).

Finally, both studies analyzed costs separate from clinical outcomes and thus were not full
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economic evaluations which are required to inform decisions on value for care and changes to
healthcare policy. To our knowledge, no studies to date have conducted full cost-effectiveness
analysis comparing both costs and outcomes of midvastus TKA compared to medial parapatellar
TKA.

A few authors have investigated the economic impact of outpatient total joint arthroplasty
(Crawdord et al., 2015). Lovald et al. (2014) conducted a retrospective cost-analysis on the
average medical costs of patients who had different lengths of stay following TKA and found
those in the outpatient group incurred $8527 less in costs attributed to knee OA compared to the
standard length of stay group over two years. They do not mention which surgical approach was
used in the procedures, although they credit the move to outpatient procedures to the use of less
invasive surgical techniques, regional as opposed to generalized anesthesia, and the
implementation of enhanced recovery pathways.

The costs associated with a minimally invasive technique for outpatient total hip arthroplasty
were compared to standard inpatient total hip arthroplasty in a study by Bertin (2005). The billed
charges of patients undergoing minimally invasive outpatient THA were found to be
approximately $4000 less compared to inpatient charges. A later study by Aynardi et al. (2014)
also found outpatient THA to have significantly fewer billed charges. In this study, both groups
underwent THA with a direct anterior approach which is a minimally invasive technique.

No full economic evaluations have yet been published on the cost-effectiveness of outpatient
TKA using either a minimally invasive or standard surgical approach. Given the lack of
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scientific consensus on the benefits of different surgical approaches for TKA, further
investigation into these techniques is warranted. The purpose of this trial was to inform the
surgical protocol of a future randomized controlled trial to study the cost-effectiveness of
outpatient TKA.
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Chapter 2
2 Methods
2.1 Study Design
We conducted cost-effectiveness analyses comparing the medial parapatellar surgical approach
to the midvastus surgical approach for TKA. In the trial, we randomized patients to either
surgical approach, with or without the use of a tourniquet using a 2x2 factorial design. This
randomization technique was used to allow us to explore surgical approach and tourniquet use
efficiently and simultaneously by including all participants in both analyses (Lubsen & Pocock,
1994; Montgomery et al., 2003). Tourniquet use was expected to act independently from costs
related to surgical approach, and results on clinical impact will be reported elsewhere. Here we
present the results of cost-effectiveness comparisons between the surgical approach groups.
All patients underwent primary total knee arthroplasty at London Health Science’s Centre,
University Hospital between August 2017 and February 2020, using a cemented Triathlon™
(Stryker Orthopaedics, Mahwah, NJ, U.S.A.) implant by two fellowship-trained arthroplasty
surgeons. We followed patients from their preoperative visit to 12 months post-surgery and
collected data on healthcare resource use and clinical outcome measures at standard of care
visits. The study was approved by the University of Western Ontario’s Research Ethics Board
for Health Sciences Research Involving Human Subjects and registered at clinicaltrials.gov
(NCT03081663).

2.2 Eligibility Criteria
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We included patients scheduled to undergo primary total knee replacement with osteoarthritis,
varus knee alignment, and an American Society of Anesthetists (ASA) score of three or less.
Patients were also required to be able to read and understand English (as printed instructions
were provided in English only), have home or cell phone access, and have an adult to accompany
them home and care for them post-operatively.

We excluded patients who were diagnosed with inflammatory arthritis, had a body mass index
(BMI) greater than 40 or less than 18, were skeletally immature, had an active or suspected latent
infection at or about the joint, had inadequate bone stock for support or fixation of the prosthesis,
hardware precluding intramedullary instrumentation, prior osteotomies of the femur or tibia, had
cognitive or neuromotor conditions, significant pain management issues, or had a family history
of anesthesia-related complications (e.g. malignant hypothermia, pseudocholinesterase
deficiency, airway difficulties, obstructive sleep apnea). Patients were also excluded if they lived
more than 90 minutes from the hospital, were without access to caregivers, were unable to go
directly to their home after surgery, or had significant psychological or social issues that would
prevent them from managing at home safely.

We included patients who met these criteria, were willing and able to comply with follow-up
requirements and self-assessments, and provided informed consent.

2.3 Randomization
Patients were enrolled in the trial at their preadmission visit to the hospital and were randomly
allocated to one of four groups: midvastus TKA, with or without a tourniquet, or standard medial
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parapatellar TKA, with or without a tourniquet, via a web-based system. We used block
randomization stratified by surgeon and patients previous experience with TKA (whether
themselves or a family member/friend they cared for post-surgery). We kept patients and research
staff blinded to group allocation until the final study visit.

2.4 Intervention
2.4.1 Operative Procedure
Both surgical approaches are currently used in the surgeons’ normal practices and are completed
using a straight anterior midline incision. Distally the approaches are the same, entering next to
the patellar tendon to the tibia, avoiding the patella. With the midvastus surgical approach,
proximally the incision extended obliquely from the superior-medial corner of the patella in line
with the muscle fibers of the vastus medialis obliquus muscle belly, allowing the quadriceps
tendon to remain intact. For the medial parapatellar approach, the quadriceps was split in line
with the quadriceps tendon fibers, leaving a 5 mm cuff of tendon medially. An intramedullary
femoral guide and extramedullary tibial guide were used for patients who were randomized to
medial parapatellar TKA. The surgeons only used computer-assisted navigation for patients who
received a TKA with the midvastus approach as implant malalignment has been a concern with
this approach. All other aspects of the surgery were kept the same between the groups.

2.4.2 Postoperative Care
All participants had to pass physiotherapy discharge criteria and followed standard postoperative
rehabilitation protocols. There was no difference in activity restrictions between both groups.
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Patients returned to the orthopedic outpatient clinic for a follow-up visit with the surgeon at two
weeks, six weeks, three months, and 12 months after surgery.

2.5 Outcome Measures
We collected outcome measures from patients at their preadmission appointment (no more than
one month prior to surgery), on the day of discharge from hospital, and at two-weeks, six-weeks,
three-months, and 12-months post-surgery. In addition to these time points, cost data were also
collected at six and nine months. We used a secure web-based data management system
(EmPower Health Research, Inc, www.empowerhealthresearch.ca) which allowed patients to
complete questionnaires online. Patients also had the option of completing hard copies of the
questionnaires at each follow-up.

2.5.1 Clinical Effectiveness
Information on clinical effectiveness was collected directly from study participants. Patients
completed the self-reported questionnaires at or no earlier than one week before each study visit.

2.5.1.1 EQ-5D-5L
The EQ-5D-5L is a preference-based health-state measure used to collect quality of life data
directly from patients (Fransen & Edmonds, 1999). Unique health states are described using a 5digit number formed according to responses in five dimensions; mobility, self-care, usual
activities, pain/discomfort, and anxiety/depression, each with five response levels (no problems,
slight problems, moderate problems, severe problems, and unable to/extreme problems)
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(Herdman et al., 2011; Janssen et al., 2013). Using a value set, which reflects the health
preferences of the general public, health utility values can be derived from the EQ-5D-5L health
states (Xie et al., 2016). Health utilities are required to estimate QALYs and are anchored at 0
(dead) and 1 (full health), although negative values are possible for health states worse than dead
(Jenkins et al., 2013; Wolowacz et al., 2016).
The EQ-5D-5L has been shown to exhibit acceptable test-retest reliability in each domain (range
0.61-0.77) in OA patients undergoing TKA (Conner-Spady et al., 2015). When compared with
the earlier EQ-5D-3L, the EQ-5D-5L has been found to have better responsiveness, stronger
convergent construct validity, and stronger correlations with the Western Ontario McMaster
Osteoarthritis Index, Oxford Knee Score, and Short Form-12 (Jin et al., 2019). Additionally,
individual EQ-5D-5L dimension response levels collected through electronic versions of the tool
have not been found to significantly differ when compared with paper versions (Mulhern et al.,
2015).

2.5.1.2 Western Ontario McMaster Osteoarthritis Index
The Western Ontario McMaster Osteoarthritis Index (WOMAC) is a disease-specific
questionnaire used to measure health status across three domains in patients with OA of the hip
or knee (Bellamy & Buchanan, 1986). The tool is self-administered and comprised of 24
questions total across three domains: five items relating to pain, two to stiffness, and 17 to
physical function. Each question is scored on a scale from 0 (none) to 4 (extreme). Domains can
be assessed individually, or they can be combined to create a global score to evaluate function
and health. WOMAC scores can be linearly transformed to a 0–100 scale, with lower scores
indicating more severe impairment (Giesinger et al, 2014).
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WOMAC is one of the most commonly used patient-reported outcome measures in patients with
knee osteoarthritis and has been found to be valid, reliable, and responsive for detecting
important health changes after total knee arthroplasty (White & Master, 2016; Walker et al.,
2019). Overall, the WOMAC has high test-retest reliability for the physical function and pain
subsections and has been found to be highly predictive for primary TKA treatment success at 12months (Faucher et al., 2004; Giesinger et al., 2014). An electronic version of the WOMAC has
been validated for use among joint replacement patients against the paper version (Marsh et al.,
2014).

2.5.2 Costs
2.5.2.1 Surgical Costs
We collected data on health care resource use at the patient level. Patients’ medical charts were
reviewed from the time of admission for TKA to discharge to retrieve time spent in the postanaesthetic care unit (PACU) and surgical inpatient ward following surgery. The cost per unit
time spent in each department was obtained from our institution’s case costing data and applied
to each case.

The remaining average costs related to the TKA procedure, included the cost of food services,
operating room, day surgery pre-and-post-operative care, clinical laboratory services, medical
imaging, respiratory services, pharmacy costs, physiotherapy, and was obtained from hospital
case costing data. Surgeon and anesthesiologist billing was also included in this total and valued
from the Ontario Ministry of Health Schedule of Benefits (Ministry of Health and Long-Term
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Care [MOHLTC], 2020). The cost of the prosthetic implant was not included as prosthesis costs
vary widely and can largely influence TKA cost. All patients in the study had cemented Stryker
Triathlon implant.

2.5.2.2 Healthcare Resource Use
Patients kept daily diaries for the first 14 days postoperative and completed self-reported cost
questionnaires at two weeks, six weeks, three-, six-, nine-, and 12-months post-surgery. Resource
use and costs were collected across 14 domains including visits to their family physician,
surgeon, and other healthcare professionals (e.g., physical therapists, occupational therapists,
etc.), information about hospitalizations and emergency room visits, diagnostics (e.g., imaging,
laboratory), medications, calls to the surgeon’s office, and any other related expenses.

To estimate costs directly covered by the provincial publicly funded healthcare, we applied the
unit prices from provincial databases. We obtained the unit prices of physician services,
including family physician and specialists from the Ontario Ministry of Health Schedule of
Benefits (MOHLTC, 2020). We valued walk-in clinic costs at the family physician fee and
valued calls to physicians or specialists which lasted at least 10 minutes as a partial assessment.
The cost of a physiotherapist visit was taken from the Ontario Quality-Based Procedures
Bundled Pricing (Health Quality Ontario & MOHLTC, 2013) if patients reported their visits
were covered by the provincial insurance. Medication costs were obtained from the Ontario Drug
Benefit Formulary (MOHLTC, 2021) or through a survey of local pharmacies.
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Self-reported costs were used if patients reported that they paid for other healthcare professional
visits or medications out-of-pocket or through private insurance.

2.5.2.3 Indirect Costs
Patients also reported information about indirect productivity losses such as the amount of timeoff paid employment, homemaking, volunteer activities, and caregiving. We also requested
patients report the number of hours of unpaid assistance received from friends or family, as well
as the hours of paid assistance they received.

We used the average Canadian wage for individuals 25 years and older reported by Statistics
Canada in June 2021 to place a monetary figure on time off from paid employment, for both
patients and their caregivers (Statistics Canada, 2021). The current value of minimum wage in
Ontario was used to value participants time away from volunteer or homemaking activities and
unpaid assistance received (Government of Ontario, 2021). We estimated the total cost for each
patient over the 12-month follow-up period and reported all costs in 2021 Canadian dollars.
Resource use for unrelated conditions was not included.

2.6 Sample Size
A formal sample size calculation was not conducted as the main goal of this pilot study was to
inform the surgical protocol of a future randomized trial investigating outpatient total knee
arthroplasty. Based on the participating surgeons’ caseload, we estimated 80 participants could
be recruited over the two-year study time frame.
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2.7 Data Analysis
We analyzed data using Stata v. 11.2 (StataCorp LP, College Station, TX, USA) and all
statistical tests were two-tailed at a significance level of 0.05.

All outcomes were tested for normality by looking at boxplots and assessing histograms for
kurtosis and skewness. We used descriptive statistics to present the demographic and surgical
characteristics for each group. We report means and standard deviation (SD) for all normally
distributed continuous measures (age, height, operative time), and frequencies and proportions
for categorical variables (sex, contralateral knee symptoms, ASA score). We reported the median
and interquartile range for non-normally distributed continuous measures.

We used non-parametric bootstrapping with 1000 replications to estimate totals if data were
skewed and presented 95% confidence intervals (CI) with standard errors (SE) (Efron, 1979;
Briggs et al. 1997; Tambour & Zethraeus, 1998; Hesterberg, 2011). We conducted the primary
analysis following the intention to treat principle.

2.7.1 Cost-effectiveness analyses
Costs are often categorized as direct medical costs, direct non-medical costs, and indirect costs.
Direct medical costs refer to the costs associated with the health services (e.g., treatment and
follow-ups, medications) which are relevant to the treatment option being considered. Direct
non-medical costs include patient out-of-pocket expenses associated with the intervention (e.g.,
travel, house modifications, and informal caregiving), while indirect costs include productivity
losses due to mortality or morbidity, (e.g., lost earnings and decreased capacity for leisure).
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We conducted cost-effectiveness analyses from both the healthcare payer (HCP) and societal
(SOC) perspectives. In Canada, we have a single-payer system where the funding and
reimbursement decisions are made by provincial governments (e.g., the Ontario Ministry of
Health and Long-Term Care) on behalf of the population covered. The HCP perspective includes
direct costs covered by the Ontario Ministry of Health Insurance Plan (e.g., visits to healthcare
professionals, procedures, tests, hospitalizations, and visits to emergency rooms). For patients
aged 65 years and older, we also included prescription medications covered by the Ontario Drug
Benefit in the HCP perspective.

The societal perspective included both direct and indirect costs (time-off paid employment,
volunteer activities, homemaking, caregiving, and caregiver assistance), as well as out-of-pocket
expenses to patients.

Once aggregated, we calculated incremental cost-effectiveness ratios (ICER) by taking the ratio
of the mean values of incremental cost by the incremental effect between the MPP and MMV
groups (ICER = ΔC/ΔE, C = cost, and E = effectiveness).

Cost-utility analyses were conducted using the difference in QALYs derived from EQ-5D-5L
utility scores as the measure of effect. QALYs are a generic outcome metric which can reflect
preference for different health effects and enables comparisons across health care interventions.
QALYs were estimated by calculating the area under the curve, which can be thought of as the
total time spent in each health state weighted by the health-related quality of life or utility value
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at that state (Drummond et al., 2015). We also conducted a cost-effectiveness analysis using
WOMAC total score at 12-months as the measure of effect.

2.7.2 Net Benefit Regression (NBR)
We used a NBR framework to allow for consideration of incremental cost and effect of the
intervention in addition to a willingness-to-pay (WTP) value (Hoch et al., 2002). A WTP value is
the maximum acceptable amount one is willing-to-pay to achieve one additional unit
improvement in effect.

Incremental net benefit (INB) was calculated using the equation: INB = WTP* DE - DC
A positive INB, or INB>0, indicates the midvastus approach is more cost-effective than the
medial parapatellar approach. Separate NBR models were developed for the HCP and societal
perspectives, and a range of willingness–to-pay values from $0 – $50,000 were considered. We
included age, sex, BMI, baseline utility, and WOMAC score as covariates in our model.

2.7.3 Uncertainty
Cost-effectiveness acceptability curves (CEAC) were also used to characterize the uncertainty
around the cost-effectiveness estimates (Hoch et al., 2006). The CEACs graphically present the
probability that TKA performed with the midvastus approach is cost-effective compared to the
medial para-patellar approach over a wide range of willingness to pay values per outcome
gained. We constructed CEACs from the healthcare payer and societal perspectives considering
willingness to pay for either QALY or WOMAC point gained.
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2.7.4 Sensitivity Analysis
We conducted one-way sensitivity analyses 1) analyzing participants who crossed over as treated
and 2) removing outliers (residuals > 2 standard deviations) from both perspectives.

2.7.5 Missing Data
We used multivariate imputation using chained equations (MICE) methods to impute missing
utility data and WOMAC scores. Estimates of total costs were also imputed for patients lost to
follow-up at 12-months. We used predictive mean matching pulling from five nearest neighbors
to generate 5 imputations which were pooled to create one final data set for analysis. To increase
the accuracy of the imputed values, age, sex, BMI, previous TKA (yes or no), and smoking
status (yes or no) were used as covariates.

2.8 Source of Funding
This study was supported by a grant from Stryker Canada and Physician Services Incorporated
(PSI).
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Chapter 3

3 Results
3.1 Patient Flow
Eighty-six patients were randomized for this study, with 40 allocated to the standard medial
parapatellar group (MPP), and 46 allocated to the minimally invasive midvastus (MMV) group
(Figure 3.1). Following randomization, one participant was excluded as they no longer met the
inclusion criteria (diagnosed with obstructive sleep apnea), and four patients requested to be
withdrawn from the study. Two patients (MMV and MPP) withdrew at the baseline visit, one
patient (MPP) withdrew at the two-week study visit, and one patient (MMV) requested to
withdraw at the six-month visit. Nine participants crossed over, with two patients in the MPP
group having TKA with a MMV approach, and seven patients in the MMV group having surgery
with the standard MPP approach.

Due to COVID-19 restrictions, some patients were missed at the six-month follow-up (26
patients in the MPP group and 27 patients in the MMV group), and at the nine-month follow-up
(15 patients in the MPP group and 24 patients in the MMV). We were able to contact the
majority (95.4%) of patients missed at the 12-month follow-up and asked patients to report all
relevant costs since their last study visit. Missing 12-month cost data values were imputed for 3
patients in the MPP group (7.9%) and 2 patients in the MMV group (4.5%). 4.6% of missing
utility data and 13.3% of missing 12-month WOMAC data values were also imputed.

30
Figure 3.1: CONSORT diagram of participant flow through the study.
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3.2 Demographics and Clinical Characteristics
Demographic and clinical characteristics were similar between the two groups across most
measures with the exception of height (p = 0.044), weight (p = 0.001), and BMI (p = 0.014)
which was significantly higher in the MPP group (Table 3.1). The mean age in the MPP group
was 67 years compared to 70 years in the MMV group, and there was a greater percentage of
male participants, although not significantly different. Majority of patients were considered to
have a severe systemic disease according to their ASA score and had symptoms of osteoarthritis
in their contralateral knee. There was also a lower proportion of patients with Charlson
Comorbidity Index scores of two or greater in the MPP group compared to the MMV group.
Table 3.1. Baseline demographics and clinical characteristics.
Characteristic
Height, cm
Weight, kg
BMI, kg/m2
Age, y
Sex (Male), n (%)
Other Knee Symptoms, n (%)
Previous TKA, n (%)
Surgery on Dominant Knee, n (%)
Smokers, n (%)
0 (never smoked)
1 (quit >12 months)
2 (quit <12 months)
3 (yes)
ASA Score, n (%)
1
2
3
Charlson Comorbidity Index
0
1
2
3

MPP TKA (n=38)
Mean (SD)
171.87 (10.51)
96.53 (18.72)
32.47 (4.16)
66.82 (7.53)
21 (55.26)
26 (68.42)
11 (28.95)
17 (44.74)

MMV TKA (n=45)
Mean (SD)
166.96 (11.18)
84 (15.58)
30.07 (4.47)
69.76 (7.29)
18 (40.00)
29 (64.44)
9 (20.00)
16 (35.56)

14 (36.84)
20 (52.63)
1 (2.63)
3 (7.90)

23 (51.11)
19 (42.22)
1 (2.22)
2 (4.44)

1 (2.63)
16 (42.11)
21 (55.26)

0
17 (37.78)
28 (62.22)

P value
0.04
>0.01
0.01
0.08
0.17
0.70
0.34
0.39
0.61

0.48

0.25
24 (63.16)
11 (28.95)
3 (7.89)
0

29 (64.44)
7 (15.56)
8 (17.78)
1 (2.22)
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3.3 Surgical Characteristics
Surgical time and time in the Post Anesthesia Care Unit (PACU) was similar between the groups
(Table 3.2). The majority of patients received spinal anesthesia while three patients in the MPP
group and one patient in the MMV group received general anesthesia. There were two patients in
the MPP group who were unable to pass physiotherapy discharge criteria after surgery and had to
remain in hospital while waiting for a transfer to a rehabilitation facility. These patients had
lengths of stays greater than 140 hours. Additionally, one participant in the MPP group was
discharged from the hospital on the same day as their surgery. As this outcome was not normally
distributed, we reported medians and interquartile ranges. The median length of stay in the MPP
group was 44.5 hours compared to 44.0 hours in the MMV group (p = 0.22).

Table 3.2. Surgical characteristics.
MPP TKA
MMV TKA
Mean (SD unless stated)
83.37 (14.45)
86.56 (17.72)
55.0 (8.79)
58.2 (8.88)

Mean Difference
(95% CI)
3.19 (-3.96, 10.34)
3.2 (-0 .67, 7.07)

Surgery Time, min
Procedure Time, min
Tourniquet Time, min
Standard Tourniquet
53.48 (8.72)
58.52 (8.72)
5.04 (-0.16, 10.25)
Minimal Tourniquet
8.24 (2.34)
13.35 (3.07)
5.12 (-2.95, 13.18)
Anaesthesia, n (%)
Spinal
35 (92.11)
44 (97.78)
General
3 (7.90)
1 (2.22)
Length of Stay, hrs,
44.50 (26.0, 50.0) 44.00 (26.0, 48.0)
median, (IQR)
Admission to PACU,
3.63 (0.91)
3.80 (0.70)
0.16 (.52, 0.19)
hrs
Time in PACU, hrs
2.65 (1.40)
2.70 (2.94)
0.05 (-1.00, 1.10)
Ward to Discharge,
42.0 (23.0, 47.0)
40.0 (22.0, 45.0)
hrs, median, (IQR)
SD = standard deviation, CI = confidence interval, IQR = interquartile range, PACU = post
anaesthesia care unit

P value
0.38
0.10
0.06
0.21
0.41
0.22
0.36
0.94
0.16
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3.4 Outcome Measures
3.4.1 Effectiveness Outcomes
Utility values were significantly higher in the MMV group compared to the MPP group at threemonths postoperative, although there was no significant difference at 12-months (Table 3.3).
WOMAC total scores were statistically significantly higher in the MMV group at both the threemonth and 12-month visits. Both utility value and WOMAC total score were slightly higher in
the MMV group at baseline, although the difference was not significant. Patients in both groups
demonstrated improvements in total WOMAC score from baseline to 12-months however the
difference in improvement did not the reach the minimally clinically important difference
(MCID) of least 10 points (Clement, 2018).

Table 3.3. EQ-5D Utility Scores and WOMAC total scores measured from baseline to 12-months
postoperative.
MPP TKA
Mean (SD)
EQ5D Utility Values
Pre-operative
Two-week
Six-week
Three-month
12-month
Mean QALYs gained
from baseline
WOMAC Total Score
Baseline
Six-week
Three-month
12-month

MMV TKA
Mean (SD)

Mean Difference
(95% CI)

P value

0.664 (0.028)
0.649 (0.025)
0.746 (0.016)
0.794 (0.017)
0.842 (0.019)

0.678 (0.034)
0.680 (0.032)
0.754 (0.023)
0.850 (0.022)
0.856 (0.023)

0.014 (-0.053, 0.080)
0.030 (-0.032, 0.093)
0.009 (-0.036, 0.054)
0.057 (0.014, 0.100)
0.014 (-0.031, 0.059)

0.69
0.34
0.70
0.01
0.59

0.798 (0.015)

0.831 (0.019)

0.033 (-0.005, 0.071)

0.09

81.83 (0.90)
87.57 (1.34)
90.62 (0.99)
93.90 (0.68)

83.49 (1.17)
89.34 (1.56)
93.01 (1.20)
96.15 (0.98)

1.66 (-0.63, 3.96)
1.77 (-1.30, 4.84)
2.39 (0.04, 4.75)
2.26 (0.33, 4.19)

0.16
0.26
0.05
0.02

*values are reported as means with the bootstrap standard error which is the standard deviation of the bootstrap
distribution – (Hesterberg, 2011)
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3.4.2 Cost Outcomes
We calculated total costs over the 12-month study period, and also costs by category (Table 3.4).
The categories with the largest differences in cost between the MPP and MMV groups were the
cost of the inpatient hospital ward stay (mean difference = -385.46, 95% CI: -940.75, 169.94; p =
0.17), and paid caregiver assistance, which are higher in the MPP group. The difference in costs
for other health care provider costs, including physical therapy and occupational therapy, was also
large between the groups however these costs were higher in the standard group from the payer
perspective, and higher in the midvastus group from a societal perspective (Table 3.4).

For the base-case analysis (participants analyzed according to intention to treat) there was a
statistically significant difference in total costs from the societal perspective favoring the
midvastus group (mean difference= -6980.95, 95% CI: -13988.45, 26.56; p = 0.05) (Table 3.5).
Participants in the midvastus group also incurred fewer costs from the payer perspective
although not statistically significant (mean difference = -463.94, 95% CI: -1110.32, 182.52; p =
0.16). When analyzed as treated, the difference in cost increases from both a payer and societal
perspective with greater costs incurred by the MPP group. However, the difference from the
payer perspective still does not reach statistical significance (mean difference = -529.20, 95% CI:
-1116.84, 58.43; p = 0.08).
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Table 3.4. Cumulative costs by categories for patients in the MPP and MMV groups (base case).
Costs

MPP TKA
Mean (SD)

MMV TKA
Mean (SD)

Hospital Costs
Average TKA Procedure
PACU

5878.36
316.25 (27.91)

5878.36
322.10 (61.47)

Ward

1493.68 (276.88)

1108.27 (283.34)

Total Hospital Costs

7640.66 (292.14)

7245.16 (306.78)

Health Professionals
Family Physician Visits

52.82 (19.57)

44.60 (26.01)

Surgeon and Specialists

108.13 (17.74)

111.03 (19.94)

Other Health Care
Professional - HCP
Other Health Care
Professional - SOC

301.05 (19.91)

263.16 (26.58)

544.15 (70.92)

742.18 (143.82)

Medication - HCP

42.94 (22.25)

56.58 (28.08)

Medication - SOC

78.37 (18.54)

109.02 (41.01)

Tests and X-Rays

97.51 (7.75)

105.68 (11.62)

Emergency Visits and
Hospitalizations
Other Out-of-Pocket
Expenses

87.65 (37.67)

40.61 (41.99)

1656.77 (1319.85)

680.01 (1352.68)

660.11 (384.01)

120.52 (385.33)

1135.77 (180.06)

984.75 (265.44)

6698.95 (1868.39)

2671.25 (2011.48)

3317.25 (865.96)

2242.38 (925.42)

Indirect Costs
Paid Caregiver
Assistance
Unpaid Caregiver
Assistance
Time-off Paid
Employment
Time-off Volunteer
Activities

Mean Difference
(95% CI)

P Value

5.85 (-114.62,
126.33)
-385.46 (-940.75,
169.94)
(-996.77, 205.78)

0.92

-8.22 (-59.18,
42.76)
2.90 (-36.18,
41.98)
-37.90 (-89.99,
14.19)
198.03 (-83.87,
479.92)

0.75

13.64 (-41.39,
68.67)
30.6463 (-49.73,
111.02)
8.17 (-14.61,
30.95)
-47.04 (-129.34,
35.27)
-976.75 (3627.95,
1674.44)

0.63

-539.59 (1294.82, 215.64)
-151.0195 (671.26, 369.23)
-4027.702 (7970.13, -85.27)
-1074.87 (2888.66, 738.92)

0.16

*values are reported as means with the bootstrap standard error which is the standard deviation of the bootstrap
distribution – (Hesterberg, 2011)

0.17
0.20

0.88
0.15
0.17

0.46
0.48
0.26
0.47

0.57
0.05
0.25
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Table 3.5. Total costs with sensitivity analyses over the 12-month study period (2021 $CAD).
MPP TKA
Mean (SD)
Payer Perspective
Base Case
8330.76 (307.08)
As Treated
8334.27 (275.96)
Outliers
Removed
7905.95 (144.96)

MMV TKA
Mean (SD)

Mean Difference
(95% CI)

P value

7866.82 (329.83)
7805.06 (299.82)

-463.94 (-1110.32, 182.52)
-529.20 (-1116.84, 58.43)

0.16
0.08

7866.83 (186.08)

-39.12584 (-403.83, 325.57)

0.83

Societal Perspective
Base Case
22078.13 (3446.42) 15097.19 (3575.32) -6980.95 (-13988.45, 26.56)
As Treated
21877.39 (3085.75) 14440.36 (3263.55) -7437.03 (-13833.47, -1040.59)
Outliers
Removed
19116.11 (2007.89) 15097.18 (2302.51) -4018.93 (-8531.77, 493.91)
*values are reported as means with the bootstrap standard error which is the standard deviation of the bootstrap
distribution – (Hesterberg, 2011)

From the payer perspective, there were three outliers with residuals greater than two standard
deviations in the MPP group; two patients who stayed greater than 140 in the hospital
postoperative, and one patient who had extreme pain and reported visits to the emergency room
at two-weeks and three-months. When these patients were removed from the analysis, there is no
apparent difference in cost between groups.
From the societal perspective there was one patient in the MPP group that reported time off work
from baseline to 12-months postoperative and the cost of hiring full time assistance. When
removed as an outlier, a large difference in cost remained in favor of the MMV approach.

0.05
0.02
0.08
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3.4.3 Cost-Effectiveness
The results of the cost-effectiveness analysis are reported in Table 3.6. From the base case costeffectiveness analysis, the incremental cost from the societal perspective was -6980.95 and the
incremental effect was 2.36, which indicates the midvastus approach dominates the standard
medial parapatellar approach (less costs on average, and more effective on average). When
patients were analyzed as treated from a societal perspective, the dominance was stronger. The
midvastus approach remained dominated across all sensitivity analysis, although results were not
statistically significant.
Table 3.6. Incremental Cost-Effectiveness of the midvastus versus medial parapatellar approach
for TKA.
Incremental Cost
(95% CI)

Incremental Effect
(95% CI)

ICER

QALYs
Healthcare Payer Perspective
Base Case
-463.94 (-1110.32, 182.52)
As Treated
-529.20 (-1116.84, 58.43)
Outliers Removed
-39.12584 (-403.83, 325.57)

0.033 (-0.005, 0.071)
0.044 (0.008, 0.080)
0.028 (-0.009, 0.065)

Dominated
Dominated
Dominated

Societal Perspective
Base Case
-6980.95 (-13988.45, 26.56)
As Treated
-7437.03 (-13833.47, -1040.59)
Outliers Removed
-4018.93 (-8531.77, 493.91)

0.033 (-0.005, 0.071)
0.044 (0.008, 0.080)
0.031 (-0.007, 0.068)

Dominated
Dominated
Dominated

WOMAC
Healthcare Payer Perspective
Base Case
-463.94 (-1110.32, 182.52)
As Treated
-529.20 (-1116.84, 58.43)
Outliers Removed
-39.12584 (-403.83, 325.57)

2.257 (0.328, 4.186)
1.908 (0.021, 3.795)
1.877 (-0.109, 3.863)

Dominated
Dominated
Dominated

Societal Perspective
Base Case
-6980.95 (-13988.45, 26.56)
As Treated
-7437.03 (-13833.47, -1040.59)
Outliers Removed
-4018.93 (-8531.77, 493.91)

2.257 (0.328, 4.186)
1.908 (0.021, 3.795)
2.092 (0.064, 4.121)

Dominated
Dominated
Dominated
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3.4.3.1 Net Benefit Regression
From both the healthcare payer and societal perspectives, the incremental net benefit was greater
than zero for all WTP values suggesting that the midvastus approach is cost-effective compared
to the standard approach (Table 3.7).
Table 3.7. Base-case net benefit regression results.
Healthcare Payer
INB (SD)
95% CI

WTP
QALYs
0
583.80 (421.92)
1000 607.68 (429.15)
2000 631.56 (437.12)
3000 655.44 (445.79)
4000 679.32 (455.13)
5000 703.21 (465.09)
10000 822.61 (522.92)
20000 1061.42 (666.54)
30000 1300.22 (830.97)
40000 1539.03 (1006.06)
50000 1777.84 (1187.10)

-243, 1410
-233, 1448
-225, 1488
-218, 1529
-212, 1571
-208, 1614
-202, 1847
-244, 2367
-328, 2928
-432, 3510
-548, 4104

Healthcare Payer
WTP INB (SD)
95% CI
WOMAC
0
583.80 (421.92)
-243, 1410
1000 2453.84 (1251.23)
1, 4906
2000 4323.88 (2248.15)
-82, 8730
3000 6193.92 (3262.49)
-200, 12588
4000 8063.95 (4281.88)
-328, 16456
5000 9933.99 (5303.42)
-460, 20328
10000 19284.19 (10421.17) -1140, 39709
20000 37984.59 (20667.08) -2522, 78491
30000 56684.96 (30915.38) -3908, 117270
40000 75385.35 (41164.28) -5295, 156065
50000 94085.74 (51413.43) -6682, 194854

Societal
P
0.17
0.16
0.15
0.14
0.14
0.13
0.12
0.11
0.12
0.13
0.13

INB (SD)

95% CI

4739.26 (3414.79)
4763.15 (3416.21)
4787.03 (3417.73)
4810.91 (3419.37)
4834.79 (3421.12)
4858.67 (3422.97)
4978.07 (3433.88)
5216.88 (3463.76)
5455.69 (3504.17)
5694.50 (3554.74)
5933.31 (3615.04)

-1953, 11432
-1932, 11458
-1911, 11485
-1890, 11512
-1870, 11540
-1850, 11567
-1752, 11708
-1571, 12005
-1412, 12323
-1272, 12661
-1152, 13018

P
0.17
0.16
0.16
0.16
0.16
0.16
0.15
0.13
0.12
0.11
0.10

Societal
P
0.17
0.05
0.05
0.06
0.06
0.06
0.06
0.07
0.07
0.07
0.07

INB (SD)

95% CI

4739.26 (3414.79)
6609.30 (3787.68)
8479.34 (4374.17)
10349.38 (5101.09)
12219.42 (5916.93)
14089.46 (6789.70)
23439.65 (11535.4)
42140.06 (21554.0)
60840.4 (31720.49)
79540.8 (41927.42)
98241.26 (52151.06)

-1953, 11432
-814, 14033
-93, 17052
351, 20347
622, 23816
781, 27397
830.69, 46048
-105, 84385
-1330, 123011
-2635, 161717
-3972, 200455

P
0.17
0.08
0.05
0.04
0.04
0.04
0.04
0.05
0.06
0.06
0.06

*values are reported as means with the bootstrap standard error which is the standard deviation of the bootstrap distribution
– (Hesterberg, 2011)
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3.4.3.2 Cost Effectiveness Acceptability Curves
The probability of the midvastus approach for TKA being a cost-effective strategy at different
willingness to pay thresholds is presented in Figure 3.2. At a willingness to pay of $0, there is a
greater than 90% chance that the midvastus approach is cost-effective when considering
improvements in QALYs or WOMAC total scores. When considering willingness to pay per
QALY, from a payer perspective the probability the midvastus approach is cost-effective is
93.5% at a WTP value of $5000, while the probability is 92.0% at the same WTP value from the
societal perspective.

From the healthcare payer perspective if the willingness to pay value is $1000 per WOMAC
outcome, the probability of cost-effectiveness is 97.5%, however as WTP goes up, the
probability the approach is cost effective slightly decreases. At a WTP value of $2000/WOMAC
the probability is 97.3%, at $5000/WOMAC it is 96.9%, and at $30000/WOMAC it is 96.5%.
From a societal perspective, the probability the midvastus approach is cost-effective is 98.1% at
a willingness to pay of $5000 per one point improvement in WOMAC total score and decreases
at higher willingness to pay thresholds.
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Figure 3.2: Base-case cost-effectiveness acceptability curve (CEACs) displaying the probability
that MMV TKA is cost-effective compared to MPP TKA from the healthcare payer and societal
perspectives, over a range of willingness to pay values A) for an additional QALY gained and B)
for an additional one-point improvement in total WOMAC score at 12 months postoperative.
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3.5 Sensitivity Analysis
In each of the sensitivity considerations, the INB was positive for all WTP values further
suggesting the midvastus approach may be cost-effective compared to the standard medial
parapatellar approach for TKA (Table 3.8). When analyzing patients as treated, at a willingness
to pay value of $0, the probability the midvastus approach is cost-effective is 95.5% and 92.8%
from the health care payer and societal perspectives respectively (Figure 3.3)

The probability the midvastus approach is cost-effective at a willingness to pay value of $0
decreases when analyzed with outliers removed. Although the incremental net benefit is greater
than zero, the confidence intervals 95% CIs around the estimate are wide, and the probability of
cost-effectiveness considering any outcome is estimated at 57.4% and 83.5% from the health
care payer and societal perspectives respectively.

42
Table 3.8. Sensitivity analysis net benefit regression results.

*values are reported as means with the bootstrap standard error which is the standard deviation of
the bootstrap distribution – (Hesterberg, 2011)
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Figure 3.3: Sensitivity analysis cost-effectiveness acceptability curves (CEAC) displaying the
probability that MMV TKA is cost-effective compared to MPP TKA from the healthcare payer
and societal perspectives with participants analyzed as treated, and with outliers removed, over
a range of willingness to pay values A) for an additional QALY gained and B) for an additional
one-point improvement in total WOMAC score at 12 months postoperative.
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Chapter 4
4 Discussion
This study aimed to estimate the cost-effectiveness of a midvastus approach for TKA compared
to the standard medial parapatellar surgical approach in patients with knee OA at 12-months
postoperative. The results of our study suggest midvastus TKA may be cost-effective compared
to medial parapatellar TKA from the payer perspective at WTP values between $1000 and
$2000, and WTP values between $2000 and $20,000 from the societal perspective.
To our knowledge, this is the first full economic evaluation of midvastus TKA incorporating
both direct and indirect costs alongside a randomized controlled trial with a 12-month follow-up.
Previous studies evaluating the costs associated with minimally invasive TKA have focused on
hospital costs and direct procedure-related costs covered by Medicaid or private insurance. Coon
et al. (2005) found MIS TKA procedure charges to be US $8600 (26%) less than standard TKA,
while King et al. (2011) found the difference in procedure cost to be US $1047 (7.2%) for
minimally invasive TKA compared to traditional TKA. Similarly, we found the average hospital
cost of patients in the MMV TKA group to be less than the hospital costs of the MPP group
(mean difference = -$395.49, 95% CI = -996.77, 205.78; p = 0.20), although the magnitude of
the difference was smaller (5.2%) and not statistically significant. There was considerable
uncertainty around our estimate, and calculation of hospital costs at the patient level is a noted
limitation of this study.
In this study, we found the difference in overall costs from the payer perspective was -463.94
(95% CI: -1110.32, 182.52; p = 0.16) in favor of the midvastus group in the base case analysis.
As there was a large variation in costs across individual patients, the 95% confidence intervals
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around our estimate did not provide the certainty to conclude whether MMV or MPP is costsaving from this perspective. It is possible these results did not reach statistical significance due
to the small sample size.
When we analyzed patients who crossed over in the group that they were treated, the differences
in average costs from the health care payer and societal perspectives increase in favor of the
midvastus group, with the 95% confidence intervals around our estimates suggesting significance
although they remained similarly wide compared to the base case. Removing outliers from the
analysis decreased the uncertainty around the cost estimates as the range of the 95% confidence
intervals decreased from $1292.84 to $729.4, and $14015.01 to $9025.68 for the payer and
societal perspective estimates, respectively. There were three outliers from the payer perspective
and one outlier from the societal perspective, all in the medial parapatellar group. With these
outliers removed, the difference in cost from the payer perspective greatly decreases, although
due to the small sample size, and the related complications experienced by the outliers, this may
be misleading.
Across all sensitivity analyses, the costs from the societal perspective remained substantially
greater in the medial parapatellar group. The difference in societal costs, which includes indirect
costs such as time off paid employment, volunteering, caregiving, and out-of-pocket expenses
for the patient or private insurance, was $6980.95 (95% CI: -13988.45, 26.56; p = 0.05) in the
base case analysis. The cost difference seen is largely due to less time off paid employment and
volunteer activities experienced by the midvastus group. The cost incurred for paid caregivers
was also substantially lower in the midvastus group (mean difference: -539.59; 95% CI: 1294.82, 215.64; p = 0.16). It is possible that the preservation of soft tissues with the midvastus
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approach enabled patients to return to work and activities of daily living sooner than MPP TKA
patients, which is similar to what has been expected in the literature on less invasive surgical
techniques (Berger et al., 2004; Bozic & Beringer, 2007). It is also possible that increased
assistance and time off were required by the MPP TKA group as they experienced more knee
pain following surgery (Zomar, 2020).
The results of our net benefit regression analysis (Table 3.7) and CEAC (Figure 3.2) further
support this conclusion, as they suggest there is over a 90% chance the midvastus approach is
cost-effective at a willingness-to-pay value of 0. When considering a one-point improvement in
WOMAC total score, the probability the midvastus approach is cost-effective is over 97.5% at a
WTP value between $1000 and $2000 from the payer perspective and between $2000 and
$20,000 from the societal perspective. At willingness to pay values greater than this, however,
the probability goes down due to the uncertainty surrounding the difference in outcome
measures. The probability that either intervention is cost-effective from any explored WTP value
considering QALYs gained as the primary outcome does not reach greater than 95% in the base
case. This is explained by the insignificant difference in QALYs gained between the two
treatment groups (mean difference: 0.033; 95% CI: -0.005, 0.071; p = 0.09).
Interestingly, the average cost incurred for other healthcare provider visits, such as physical
therapy and occupational therapy visits, was greater in the midvastus group from the societal
perspective. Based on the suggested quicker rehabilitation with less invasive surgical
approaches, we expected to see fewer costs associated with physical therapy in the midvastus
group.
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Similarly, a reduction in the use of pain-relief medications has previously been reported in
studies comparing minimally invasive joint arthroplasty to standard arthroplasty (Aslam et al.,
2017; Laskin, 2005); however, few have investigated the long-term medication requirements or
the costs associated. Our results indicate that over a 12-month time frame, the average cost of
medications incurred by the MMV TKA group was higher than the MPP TKA group, although
the difference was not significant. However, in our study, medications given prior to hospital
discharge were not costed at the patient level. Medication use information was collected from
patients following discharge, and the average cost of medications given to TKA patients in the
hospital was used, which likely influenced results.
The average time in the PACU and the inpatient ward was not significantly different between
groups. This is similar to findings on the length of stay in most meta-analyses comparing the
medial parapatellar and midvastus surgical approaches. Liu et al. (2014) and Xu et al. (2014)
included the results of five randomized controlled trials comparing the two approaches and found
no significant difference in hospital stay (p = 0.79).
Unlike many studies, however, we did not find a statistically significant difference in operative
and tourniquet times between the groups. Meta-analyses by Alcelik et al. (2012), Xu et al.
(2014), and Liu et al. (2014) have all found significant differences (p<0.05) in the operative
times between the two approaches, although there was significant heterogeneity among the
studies included in all three analyses. These findings may be due to the inclusion of learning
curve patients in included clinical studies. Studies investigating the learning curve associated
with less invasive surgical approaches have found that operative times are substantially longer in
the first 25 patients, however, once surgeons gain familiarity, operating times do decrease, and
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eventually, no differences in surgical time are found after surgeons received adequate training
(Migliorini et al., 2020). A meta-analysis by Onggo et al. (2020) also found significantly
increased operative times for the MMV approach, although they noted this might be due to a
variety of administrative factors, skin closure technique, and surgeon factors within the operating
room, rather than the direct result of the technical demands of the MMV surgical approach.
In both groups, there were improvements in WOMAC total scores relative to baseline at all
follow-ups. Although the mean difference in total WOMAC score between groups at 12-months
was statistically significant, it was not clinically significant. Clement et al. (2018) suggest a
minimally clinically important difference (MCID) value of 10 for WOMAC total score after
TKA. If considering a clinically important improvement of 10 points in WOMAC total score the
midvastus approach is likely cost-effective at WTP values of $10000 from the payer perspective
and between $30000 and $100000 from the societal perspective.
Compared to the literature, this study found that patients receiving MMV TKA had similar
short-term outcomes but gains in WOMAC total and quality-of-life compared to MPP TKA
patients farther out from surgery. In a study by Karpman & Smith (2009), 59 patients were
randomized to receive MPP TKA, MMV TKA, or minimally invasive quadriceps sparing TKA
and followed for two years. Although they found no difference in WOMAC scores in the MMV
TKA group, compared to the MPP TKA group, they found the minimally invasive quadriceps
sparing group demonstrated greater improvements in WOMAC pain and function scores up to
three-months postoperative. Nestor et al. (2010) also found no difference in WOMAC or 12-Item
Short Form Health Survey (SF-12) scores at any time from pre-operative to three-months
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postoperative, although their study was conducted with 27 patients undergoing bilateral TKA
with the MMV versus MPP approaches.
Lin et al. (2020) recently compared the two approaches using the Forgotten Joint Score (FJS).
The FJS is another patient-reported outcome measure (PROM) tool developed for THA and
TKA patients to assess awareness of the artificial joint, which can reflect patient satisfaction
(Behrend et al, 2012; Thienpont et al., 2014). They found significant differences between the
groups in favor of the midvastus approach at all follow-ups during the three-year study period.
Although the tools are not perfectly comparable, this further supports the notion that patients'
priorities after TKA may not be reflected well in conventional outcomes (Lin et al., 2020).
Few other studies have reported on the long-term differences in PROMs, such as tools evaluating
health-related quality-of-life between the surgical approaches. Most meta-analyses have focused
on comparing the approaches using outcomes such as the visual analog scale, Knee Society
Score, knee range of motion, time to straight leg raise, operative time, lateral retinacular release
time, blood loss, hospital stay, and postoperative complications (Alcelik et al., 2012; Liu et al.,
2014; Xu et al., 2019).
We have previously reported on the trajectory of pain, function using the timed up and go (TUG)
test, motor power, and spatiotemporal gait outcomes experienced by our study population
(Zomar, 2020). In these functional outcome measures, our findings were more in line with the
existing literature (Alcelik et al., 2012; Liu et al., 2014; Xu et al., 2014; Aslam et al., 2019) as we
found MMV TKA patients experience less pain early in the recovery period, although there was
no difference in pain at two weeks and all outcomes at 12-weeks compared to MPP TKA
patients.

50

4.1 Strengths and Limitations
There are several limitations to this study that should be acknowledged. Although this was a
randomized trial and patient profiles were generally similar in both groups, there were a few
differences in baseline characteristics (Table 3.1). Mean height (p = 0.044), weight (p = 0.001),
and BMI (p = 0.014) were significantly higher in the MPP group when considering groups as
randomized. When analyzing patients who crossed over in the group that they were treated, the
difference in mean BMI reduces but remains significant (p = 0.049). In order to minimize the
impact of these differences, we evaluated cost-effectiveness with adjustment for baseline
variables (i.e., age, BMI, baseline WOMAC total score as covariates in the net benefit regression
model).
One major limitation to this study was the small sample size. As the main purpose of the trial
was to inform the surgical protocol of a future randomized controlled trial comparing outpatient
to inpatient TKA, we recruited patients over two years to gain a preliminary understanding of
functional recovery. We did not find significant differences in the trajectory of recovery at 12weeks between MMV TKA and MPP TKA, suggesting either approach could be used to enable
outpatient discharge. However, the results of this cost-effectiveness analysis indicate that over a
one-year time period a difference in costs and outcomes may exist, although a larger sample size
would provide greater certainty around estimates. The generalizability of this study may also be
limited by the stringent inclusion criteria and the fact that all surgeries were performed at a single
centre by arthroplasty surgeons who perform TKA at a high volume. Surgeon expertise may
have resulted in improved surgical outcomes and lower complication rates.
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Another limitation of this study was that all hospital costs could not be calculated at the patient
level. In the present study, the same implant was used for patients in both groups, therefore
implant costs should be equal. Computer-assisted navigation was used for the midvastus group
however given the expected cost of navigation (approximately $100 to $150 per patient) it is
unlikely to have a large impact on the overall costs at one-year postoperative. Although not
required to perform the midvastus approach, new surgical instrumentation and implants, as well
as navigation systems and patient-specific instrumentation, have been developed for minimally
invasive TKA (Migliorini et al., 2020). Further investigation on the cost-effectiveness and
clinical advantages of these new tools is needed as the uncertainty around them has discouraged
many surgeons from using less invasive techniques for TKA (Karachalios et al., 2008; Migliorini
et al., 2020).
Another possible limitation is the use of the self-reported resource utilization questionnaires
administered at various intervals and missed check-ins due to COVID-19 restriction, making our
data susceptible to recall bias. However, the demographics of those missed at six and nine
months were not significantly different from the rest of the study population, and most were
successfully contacted at the 12-month follow-up. Additionally, any limitations associated with
the calculation of costs should apply equally to both study groups.
A strength of this study was the use of a patient-blinded randomized design. To limit possible
bias, both participants and research staff were kept blinded to group allocation until the
participants reached the final study visit. Additionally, our effectiveness measures were patientreported, and no interpretation of data was required. We did have some cross-over between
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groups which is a noted limitation, although when analyzed in the group they were treated,
results did not significantly change.
Another strength of this analysis was that we included indirect costs to patients and caregivers in
the societal perspective. In a review on the economics of minimally invasive total joint
arthroplasty, Bozic et al. (2007) highlights the importance of considering time to recovery and
return to work. We are seeing the population of TKA patients getting younger, and the
proportion of patients undergoing TKA who are active in the workforce is growing (Maradit
Kremers et al., 2015). Additionally, as it is estimated that 80% of the overall costs related to OA
are related to time off work and leisure activities for both patients and their caregivers (Gupta et
al., 2005), understanding the costs related to productivity loss following TKA is important.
Possibly the greatest strength of this study was that costs were collected and analyzed
simultaneously with both generic and disease-specific patient-reported outcome measures. Full
economic evaluations are necessary to understand the value for money and ensure patients are
getting the best care given available resources. Additionally, using the net benefit regression
framework allowed us to determine the likelihood of cost-effectiveness across a range of
willingness to pay values.
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Chapter 5
5 Conclusion
At 1-year postoperative, midvastus TKA patients had higher WOMAC scores as well as lower
average societal costs compared to medial parapatellar TKA patients. However, we cannot
conclude with certainty that MMV TKA is cost-effective compared to MPP TKA. A long-term
prospective study with an adequately powered sample size is necessary to determine the costeffectiveness of MMV TKA and MPP TKA in the osteoarthritis patient population.

5.1 Future Directions
This analysis was conducted using data from a pilot study where the purpose was to inform the
surgical protocol of a future randomized controlled trial investigating the clinical and costeffectiveness of outpatient versus inpatient TKA. This trial will include more than 500 TKA and
THA patients to estimate the safety and cost-effectiveness of outpatient arthroplasty over a 12month follow-up period.
Establishing the safety and cost-effectiveness of outpatient TKA is essential as the prevalence of
OA and the scarcity of healthcare resources continue to increase. Additionally, although reducing
costs and freeing up hospital resources is a motivating factor for reducing the length of stay,
existing literature also suggests that patients prefer to recover at home and have decreased length
of rehabilitation (McDonald et al., 2014).
During the COVID-19 pandemic, many joint replacement surgeries were cancelled to provide
additional hospital capacity to care for COVID-19 patients (CIHI, 2021). Delayed surgeries can
significantly impact the quality of life of patients waiting for joint replacement, who have lived
many years with the debilitating symptoms of OA. Outpatient total joint replacement is a
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possible solution to allow patients to receive timely treatment while reducing the need for
inpatient hospital beds. Despite a lack of evidence supporting the safety and cost-effectiveness of
outpatient arthroplasty, the number of outpatient TKAs performed doubled during the COVID19 pandemic, although they still only represented 1.3% of all knee replacements (CIHI, 2021).
High-quality randomized control trials with full economic evaluations are needed to fully
evaluate outpatient total joint arthroplasty and increase implementation (Zomar et al., 2020).
The results of an earlier analysis on our study population found no significant differences in the
trajectory of recovery between the MMV and MPP groups during the early postoperative period
(Zomar, 2020). These findings were used to support the decision to use either surgical approach
in outpatient TKA study patients.
As the medial parapatellar and midvastus surgical approaches are the two most commonly used
approaches for TKA, not restricting surgeons to one approach increases the generalizability of
future results. However, given the differences in cost and effect seen between patients in the
MPP and MMV groups at 12-months, the effect of surgical approach on long-term outcomes and
cost should be considered in the analysis of future studies.
This study highlights the importance of investigating patient-reported outcomes measures
beyond the initial recovery period. Additionally, indirect costs should be considered along with
resource use to get better estimates of the economic impact. Future studies with larger sample
sizes can also provide more accurate estimates of patient-reported health outcomes and the costeffectiveness of using different surgical approaches for TKA in osteoarthritis patients.
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Appendix B: EQ-5D-5L descriptive system

CAPS TKA Pilot

Database ID: __________
Date: ________________
EQ-5D

Under each heading, please tick the ONE box that best describes your health TODAY.
MOBILITY
I have no problems in walking about

☐

I have slight problems in walking about

☐

I have moderate problems in walking about

☐

I have severe problems in walking about

☐

I am unable to walk about
SELF-CARE
I have no problems washing or dressing myself

☐

I have slight problems washing or dressing myself

☐

I have moderate problems washing or dressing myself

☐

I have severe problems washing or dressing myself

☐

☐

I am unable to wash or dress myself
☐
USUAL ACTIVITIES (e.g. work, study, housework, family or leisure activities)
I have no problems doing my usual activities
☐
I have slight problems doing my usual activities

☐

I have moderate problems doing my usual activities

☐

I have severe problems doing my usual activities

☐

I am unable to do my usual activities
PAIN / DISCOMFORT
I have no pain or discomfort

☐

I have slight pain or discomfort

☐

I have moderate pain or discomfort

☐

I have severe pain or discomfort

☐

I have extreme pain or discomfort
ANXIETY / DEPRESSION
I am not anxious or depressed

☐

I am slightly anxious or depressed

☐

I am moderately anxious or depressed

☐

I am severely anxious or depressed

☐

I am extremely anxious or depressed

☐
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Appendix C: Western Ontario and McMaster Universities Osteoarthritis Index

CAPS TKA Pilot

Database ID: __________
Date: ________________
WOMAC

A. Think about the pain you felt in your hip/knee during the last 48 hours.
Question: How much pain do you have?
1. Walking on a flat surface
2. Going up or down stairs
3. At night while in bed, pain disturbs your
sleep
4. Sitting or lying
5. Standing upright

None
0
0
0

Mild
1
1
1

Moderate
2
2
2

Severe
3
3
3

Extreme
4
4
4

0
0

1
1

2
2

3
3

4
4

B. Think about the stiffness (not pain) you felt in your hip/knee during the last 48 hours. Stiffness is a
sensation of decreased ease in moving your joint.
6. How severe is your stiffness after first
awakening in the morning?
7. How severe is your stiffness after sitting,
lying, or resting later in the day?

None
0

Mild
1

Moderate
2

Severe
3

Extreme
4

0

1

2

3

4

C. Think about the difficulty you had in doing the following daily physical activities dues to your
hip/knee during the last 48 hours. By this we mean your ability to move around and look after
yourself.
Question: What degree of difficulty do you
have?
8. Descending stairs
9. Ascending stairs
10. Rising from sitting
11. Standing
12. Bending to the floor
13. Walking on a flat surface
14. Getting in and out of a car, or on or off a
bus
15. Going shopping
16. Putting on your socks or stockings
17. Rising from bed
18. Taking off your socks or stockings
19. Lying in bed
20. Getting in or out of the bath
21. Sitting
22. Getting on or off the toilet
23. Performing heavy domestic duties
24. Performing light domestic duties
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None

Mild

Moderate

Severe

Extreme

0
0
0
0
0
0
0

1
1
1
1
1
1
1

2
2
2
2
2
2
2

3
3
3
3
3
3
3

4
4
4
4
4
4
4

0
0
0
0
0
0
0
0
0
0

1
1
1
1
1
1
1
1
1
1

2
2
2
2
2
2
2
2
2
2

3
3
3
3
3
3
3
3
3
3

4
4
4
4
4
4
4
4
4
4

77
Appendix D: Cost Questionnaires

CAPS TKA Pilot

Database ID: _______________

Daily Diary
1) Did you call the hospital for any reason related to your knee today?
No

Yes

S ge n

ffice

Resident on call
Other (Please specify):
1b) Reason for call?
1c) Length of Call?
2) Please record what medications you have taken today:
Medication Name

Dose

Frequency (Dose/Day)

3) Have you received assistance from a relative or a friend for health care, personal care, shopping,
household activities or transportation? (Only list assistance needed because of your knee)
No
Health Care Activity

Yes (Please Specify):
Number of hours of
assistance

Number of hours that person
took off paid employment

Taking Medications
Exercises/Rehabilitation
Dressing/Undressing
Bathing/Showering
Going to the bathroom
Shopping
Meal preparation
Housework
Finances
Doctor appointments
Driving
Other:
4) Did you incur any other expenses related to your knee, that we have not asked you about? Remember to
include things like walking aids, gasoline, taxi, ambulance, parking, food, toiletries, etc)
No

Yes (Please Specify):
Expense

Cost ($)

5) How bad is your pain today? Please mark your pain with a slash across the line ( / )
No Pain

0
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100

Severe Pain
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CAPS TKA Pilot

Database ID: __________
Date: ________________
Emergency Room Visits and Hospitalizations

1. Since your last visit, have you visited an emergency room for any reason?
No – Skip to Question 2
Yes – How many times?

If yes, which hospital did you go to and why?

1 Reason:
Hospital:
2 Reason:
Hospital:
2. Since your last visit, have you been admitted to the hospital overnight for any reason
(including overnight emergency room visits)?
No – Skip to Question 3
Yes – How many times?
Admission Date:

Please complete the following:
Discharge Date:

Days in ICU/CCU:
Major surgery /
procedure if any:
Reason:
Hospital:
Discharged to:
Family Doctor Visits
3. Since your last visit, have you seen your family doctor for any reason?
I do not have a family physician - skip to Question 4
I have not attended an appointment with my family physician since my last visit
(skip to Question 4)
Yes, I have attended an appointment with my family physician since my last visit.
Number of visits:
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CAPS TKA Pilot

Database ID: __________
Date: ________________

Visit 1: Reason:
Check this box if the reason for visit was related to your knee replacement
Visit 2: Reason:
Check this box if the reason for visit was related to your knee replacement
Specialist Visits and Outpatient Clinics
4. Since your last visit, have you visited a specialist for any reason (please include visits to
the surgeon who performed your knee replacement)? If you are uncertain about the exact number
of visits, please provide your best estimate.
No – Skip to Question 5
Yes – Complete the following:
How many specialists? _______________
1:

Specialist Visited: ________________________________________________________
Number of Visits: ________________________________________________________
Please specify reason for visit: ______________________________________________

2:

Specialist Visited: ________________________________________________________
Number of Visits: ________________________________________________________
Please specify reason for visit: ______________________________________________

5. Since your last visit, have you visited any clinics for any reason (for example walk-in or
pain management clinics)? If you are uncertain about the exact number of visits, please provide
your best estimate.
No – Skip to Question 6
Yes – Complete the following:
Type of clinic visited

Version: 06-Sep-2017

Reason for Visit

Number of
visits

Number of visits
relating to your knee
replacement?
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Database ID: __________
Date: ________________
Other Health Care Professionals

6. Since your last visit, have you seen any other health professionals (like a physiotherapist,
occupational therapist, etc)? If you are uncertain about the exact number of visits, please
provide your best estimate.
No – Skip to Question 7
Yes – Complete the following:
Since your last visit, how many times have you visited a physiotherapist? ___________
Was this visit because
of your knee
replacement?

Cost of this
visit

How was the visit paid for?

Yes

No

$

OHIP

Out of pocket

Private insurance

Yes

No

$

OHIP

Out of pocket

Private insurance

Yes

No

$

OHIP

Out of pocket

Private insurance

Yes

No

$

OHIP

Out of pocket

Private insurance

Since your last visit, how many times have you visited an occupational therapist? _______
Was this visit because
of your knee
replacement?

Cost of this
visit

How was the visit paid for?

Yes

No

$

OHIP

Out of pocket

Private insurance

Yes

No

$

OHIP

Out of pocket

Private insurance

Since your last visit, how many other health professionals have you visited (for example a
chiropractor, massage therapist or community nurse)? ___________
Specialist
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Number
of visits

Number of
visits related to
your knee
replacement?

Cost of
each visit

How was the visit paid for?

$

OHIP
Private insurance
Out of pocket

$

OHIP
Private insurance
Out of pocket

$

OHIP
Private insurance
Out of pocket
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CAPS TKA Pilot

Database ID: __________
Date: ________________
Tests, Procedures, and Surgeries

7. Since your last visit, have you had any tests, procedures, or surgeries for any reason (for
example x-rays or blood tests)?
No – Skip to Question 8
Yes – Complete the following:
Test, procedure, or
surgery

Number
of tests

Number of tests
related to your
knee
replacement?

Where did you receive this test or
procedure?

Emergency room

Hospital, inpatient

Hospital, outpatient

Rehab Centre

Other, specify:
Emergency room

Hospital, inpatient

Hospital, outpatient

Rehab Centre

Other, specify:
Employment Status and Time-Off Work from Paid Employment
8. When you were enrolled in this study, were you actively employed?
No - skip to Question 10
Yes
9. Which of the following best describes your employment status or main activity at the
time of study enrollment?
Employed (full time)
Employed (part time)
Homemaking
Student
Volunteer
Social Assistance

Retired
Accident Insurance
Government
WSIB
Litigation
Disability

Temporary Sick Leave
Self-Employed
Other:
__________________

What was your occupation? ____________________________________________
10. Has there been any change to your employment status since your last visit?
No - skip to Question 11
Yes – Please complete the following:
What is your current occupation? __________________________________________
Version: 06-Sep-2017
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Database ID: __________
Date: ________________

11. Since your last visit, how much time off paid employment did you take off as a result of
your health? (includes hospitalization, doctor / emergency visits, treatment, and rehabilitation)
Days
Hours
None
12. What best describes your annual household income?
<$20,000
$20,000-$40,000
$40,000-$60,000

$60,000-$80,000
$80,000-$100,000
>$100,000
Homemaking and Volunteer Activities

13. Since your last visit, how much time off homemaking activities did you take off as a
result of your health (including hospitalization, doctor / emergency visits, treatment, and
rehabilitation)?
Days
Hours
None
14. Since your last visit, how much time off volunteer activities did you take off as a result
of your health (including hospitalization, doctor / emergency visits, treatment, and
rehabilitation)?
Days
Hours
None
15. This section is asking about your role as a primary caregiver.
Definition: Primary caregiver is an individual who is responsible for providing care
assistance, companionship, and/or supervision to another person.
Since your last visit,
I have not been a primary caregiver - skip to Question 16
I have been a primary caregiver. My role has NOT changed
If you had to take days off from primary caregiving, how many days did you take
off because of your knee (including hospitalizations, doctor visits, treatment and
rehabilitation)?
Days
Hours
None
Version: 06-Sep-2017
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Database ID: __________
Date: ________________

I was a primary caregiver and now I am NO LONGER a primary caregiver
Date of change: |___|___|___|___|/|___|___|___|/|___|___|
yyyy
/ mmm / dd
Reason for no longer being a primary caregiver:

I was NOT a primary caregiver and now I AM a primary caregiver
Date of change: |___|___|___|___|/|___|___|___|/|___|___|
yyyy
/ mmm / dd
Reason for becoming a primary caregiver:

How many days of primary caregiving did you provide?
Days
Hours
None
Assistive Living
16. Since your last visit, has there been a change to your living status? (for example, did you
move in with a relative, move into a rehabilitation facility or move back home?)
No – Skip to Question 17
Yes – Complete the following:
Is the change in living status related to your knee replacement?
Yes

No – skip to Question 17

If yes, which option best describes the change in your living status:
Living in own home – no hired assistance
Date Changed:
Living in own home – hired assistance required
Date Changed:
Please indicate the source of funding and total charge.
Publicly funded
$
Insurance funded $
Private funded
$
Living in relative s home – no hired assistance
Date Changed:
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Database ID: __________
Date: ________________
Living in relative s home – hired assistance required
Date Changed:
Please indicate the source of funding and total charge.
Publicly funded

$

Insurance funded $
Private funded

$

Supportive housing / personal care home
Date Changed:
Type of assisted living:
Assisted living (group home, retirement home)
Residential care
Long-term care facility, convalescent care, nursing home
Please indicate the source of funding and total charge.
Publicly funded

$

Insurance funded $
Private funded

$

17. Did you incur any other expenses related to your knee replacement that we have not
asked you about? (e.g. gasoline, walking aids, meals, accommodation, parking, etc)
No
Yes – please specify, with approximate cost:
Expense:

$ cost:

Expense:

$ cost:

Expense:

$ cost:

Expense:

$ cost:
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Database ID: __________
Date: ________________
Medications

18. Since your last visit, have you taken any prescription or over-the-counter medications
for your knee?
No – Skip to Question 19
Yes – Complete the following:
Yes

No
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

Medication

Dose (mcg, mg,
g, other)

Pills/dose

Doses/day

How many
days?

Pills/dose

Doses/day

How many
days?

Aspirin
Celebrex
Indomethacin
Ibuprofen (Advil)
Diclofenac (Arthrotec)
Mobicox (Meloxicam)
Naproxen (Naprosyn)
Other, specify:
Yes

No
Steroids (please list)

Name of steroid
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Dose (mcg, mg,
g, other)
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Yes

Database ID: __________
Date: ________________

No
Anti-Rheumatoid Drugs

Medication

Dose (mcg, mg,
g, other)

Pills/dose

Doses/day

How many
days?

Dose (mcg, mg,
g, other)

Pills/dose

Doses/day

How many
days?

Plaquenil (hydroxychloraquine)
Aralen (chloroquine)
Arava (Leflunomide)
Rheumatrex (Methotrexate)
Azulfidine (Sulfasalazine)
Remicade (Infliximab)
Enbrel (Etanercept)
Humira (Adalimumab)
Other
Yes

No
Pain Killers

Medication
Tylenol Regular Strength
Tylenol Extra Strength
Tylenol 2, 3
Percocets
Tramacet
Hydromorphone (Dilaudid)
Gabapentin
Lyrica
Oxycodone
Other
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Database ID: __________
Date: ________________

19. Since your last visit, did you take any other medications? Examples would include
antibiotics related to your knee replacement, or medications to prevent blood clots (i.e. Fragmin,
Xeralto, Pradaxa).
No – Skip to Question 20
Yes – Please record the name of the medication or D.I.N. number (Drug Identification
Number – found at the bottom of the prescription label on your medication bottle),
number of pills per dose, doses per day, start date of the medication, and end date for
each medication.
Medication
/DIN

Dose
(mcg, mg,
g, other)

Pills/d
ose

Doses/d
ay

Start / End date

Start:

How did you pay for
this medication?
OHIP
Private insurance
Out of pocket

End:

OHIP
Private insurance
Out of pocket

Start:
End:

OHIP
Private insurance
Out of pocket

Start:
End:

OHIP
Private insurance
Out of pocket

Start:
End:
Assistance from Others

20. Since your last visit, have you received assistance from a relative or a friend for health
care, personal care, shopping, household activities, or transportation because of your
health?
No
Yes – Complete the following:
Health Care Activity

Number of
hours of
assistance

Assistance needed
because of knee
replacement?

Taking Medications

Yes

No

Exercises / Rehab

Yes

No

Other:

Yes

No
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Number of
hours of
assistance

Assistance needed
because of knee
replacement?

Dressing/Undressing

Yes

No

Bathing/Showering

Yes

No

Going to the bathroom

Yes

No

Yes

No

Grooming (hair,
shaving)
Shopping/Home Activity

Number of
hours of
assistance

Assistance needed
because of knee
replacement?

Shopping (groceries)

Yes

No

Meal Preparation

Yes

No

Housework

Yes

No

Managing Finances

Yes

No

Other:

Yes

No

T an o a ion o he

Number of
hours of
assistance

Assistance needed
because of knee
replacement?

Doctor

Yes

No

Physiotherapist

Yes

No

Bank

Yes

No

Other:

Yes

No
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